ANORO ELLIPTA
LAMALABA DPI
Umeclidinium / Vilanterol · GlaxoSmithKline
Active Medication & Mechanism
- Umeclidinium bromide LAMA62.5 mcg per blister
Long-acting muscarinic antagonist (anticholinergic). Blocks M3 muscarinic receptors on airway smooth muscle, inhibiting acetylcholine-mediated bronchoconstriction.
- Vilanterol trifenatate LABA25 mcg per blister
Long-acting beta2-adrenergic agonist. Stimulates beta2-receptors producing sustained bronchodilation (≥24 hours at once-daily dosing).
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
62.5/25 mcg
1 inhalation once daily → 62.5/25 mcg
FDA Approved
Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Not Approved
Anoro Ellipta is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious asthma-related events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
62.5/25 mcg 1 inhalation once daily → 62.5/25 mcg
COPD FDA Approved
Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Asthma Not Approved
Anoro Ellipta is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious asthma-related events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not indicated for relief of acute bronchospasm. Use a SABA.